星太链集团中期报告 2025-2026

(Formerly known as Innovative Pharmaceutical Biotech Limited)(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)()()(Stock Code399 ) INTERIM REPORT2025/26 Contents目錄 2Corporate Information4Management Discussion and Analysis11Other Information Provided inAccordance with the Listing Rules15Condensed Consolidated Statementof Profit or Loss and OtherComprehensive Income17Condensed Consolidated Statement ofFinancial Position20Condensed Consolidated Statement ofChanges in Equity22Condensed Consolidated Statement ofCash Flows23Notes to the Condensed ConsolidatedFinancial Statements Corporate Information公司資料 BOARD OF DIRECTORS Yeung Yung(Chairman)Gao Yuan XingTang RongLi Jiehong (resigned on 7 April 2025)Qi ShujuanLong Fai (appointed on 7 April 2025)Wu Ming (appointed on 7 April 2025)Zhang Shen(appointed on 11 April 2025) Non-executive DirectorsJiang Nian (resigned 7 April 2025)Zhang Yi(appointed on 11 April 2025) Independent Non-executive Directors Chen WeijunWang RongliangChen JinzhongXia Tingkang, Tim(appointed on 7 April 2025)Sun Sizheng(appointed on 11 April 2025) Audit CommitteeChen Weijun(Chairman)Wang RongliangChen Jinzhong Remuneration CommitteeWang Rongliang(Chairman)Yeung YungChen Jinzhong Nomination Committee Yeung Yung(Chairman)Wang RongliangChen JinzhongChen Weijun HONORARY CHAIRMANMao Yumin 2STARCOIN GROUP LIMITED2025/26 Interim Report Corporate Information COMPANY SECRETARYPoon Hon Yin Clarendon House2 Church StreetHamilton HM 11, Bermuda REGISTERED OFFICE Clarendon House2 Church StreetHamilton HM 11, Bermuda PRINCIPAL PLACE OF BUSINESS INHONG KONG 145202002 Unit 2002, 20th floorOn Hong Commercial Building145 Hennessy RoadWan Chai, Hong Kong PRINCIPAL SHARE REGISTRAR ANDTRANSFER AGENT Conyers Corporate Services(Bermuda) LimitedClarendon House2 Church StreetHamilton HM 11, Bermuda Conyers Corporate Services(Bermuda) LimitedClarendon House2 Church StreetHamilton HM 11, Bermuda BRANCH SHARE REGISTRAR ANDTRANSFER AGENT IN HONG KONG 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong PRINCIPAL BANKERBank of Communications Co., Ltd. STOCK CODE399 399 www.starcoingroup.comwww.irasia.com/listco/hk/starcoingroup COMPANY WEBSITEwww.starcoingroup.comwww.irasia.com/listco/hk/starcoingroup Management Discussion and Analysis 管理層討論及分析 GROUP RESULTS 3,200,0003,000,0005.8%116,100,000101,700,000 Revenue of the Group for the Financial Period amountedto approximately HK$3.2 million, representing an increaseof approximately 5.8% as compared with the total revenueof approximately HK$3.0 million that was recorded inthe Previous Financial Period. The increase was mainlyattributable to the increase in business of the trading ofbeauty and health products segment during the FinancialPeriod. The Group recorded a loss attributable to theowners of the Company amounted to approximatelyHK$116.1 million for the Financial Period as compared toprofit of HK$101.7 million in Previous Financial Period. Theprofit of in the Previous Financial Period was attributableto the non-cash item result from the completion of theamendment of Convertible Bonds. BUSINESS REVIEW Trading of beauty and health products 3,200,0003,000,0005.8% During the Financial Period, revenue arising from the tradingof beauty and health products amounted to approximatelyHK$3.2 million, representing an increase of 5.8% from therevenue in the amount of approximately HK$3.0 millionthat was recorded in the Previous Financial Period. Duringthe Financial Period, the Group engaged a registeredpharmacist to formulate dietary supplements for the insulinhealth and blood sugar management. In September 2025,the Group already lunched its own health supplementproduct under the brand of “Pancreon PRO”. Research and development The in-process research and development project (the“In-process R&D”) represented an in-process research anddevelopment project involving an oral insulin product (the“Product”). The Group will inject additional resources intoclinical trial of the In-process R&D and consolidate the effortof the project team in order to facilitate the development ofit. 1,076,000,000 The In-process R&D was recorded as intangible asset inGroup’s consolidated statement of financial position withnet carrying value of HK$1,076 million. The managementperforms the impairment assessment at the end of eachreporting period. Management Discussion and Analysis管理層討論及分析 At the end of the Financial Period, the Directors of theCompany have performed impairment assessment on theintangible asset. The recoverable amount of the intangibleasset is determined based on the estimated fair value of theIn-process R&D. Based on the assessment, the recoverableamount of the Group’s intangible asset is estimated to behigher than the carrying amount and therefore the Directorsof the Company considered that no further impairment isnecessary as at 30 September 2025. The enrolment of the first